Truist Price Target Hike on Eli Lilly Signals ETF Rebalancing Pressure

Truist has officially raised its price target for Eli Lilly, a move driven by the robust performance and market penetration of the company's incretin-based therapies. As Eli Lilly continues to command a significant portion of the market cap in…